Today, the U.S. Food and Drug Administration approved Trogarzo (ibalizumab-uiyk), a new type of antiretroviral medication for adult patients living with HIV who have tried multiple HIV medications in the past (heavily treatment-experienced) and whose HIV infections cannot be successfully treated with other currently available therapies (multidrug resistant HIV, or MDR HIV).Trogarzo is administered intravenously once every 14 days by a trained medical professional and used in combination with other antiretroviral medications. Continue reading.
miércoles, 7 de marzo de 2018
Press Announcements > FDA approves new HIV treatment for patients who have limited treatment options
Press Announcements > FDA approves new HIV treatment for patients who have limited treatment options
![](https://blogger.googleusercontent.com/img/proxy/AVvXsEh74P7qmkHBRpE8WNBcdtmoF4O4P2HZ9uo-EHu3Z14pgHl0F-3baqeESxDF5edkC7CTsV3P64y2x8_VHLpk9mFz586mK5h-JBrTcc3WcW6mBYBuMkqvjF5bHehyphenhyphenmGcZ7tN1ZDDHX4xGRe9uFar0R_9NIQ7ZNZBSue6ew-JssvTJxaTx_A-An0poefzEGHsaQZ5KRvIdlNhYIfZyz1rkaPbhfJN-BYYYSwsEkTtxaMckaStezXt3upwHw7gFDHyabUCneQDND9i5iLzjIc1VSFxAZK2Hphpb1g=s0-d-e1-ft)
Today, the U.S. Food and Drug Administration approved Trogarzo (ibalizumab-uiyk), a new type of antiretroviral medication for adult patients living with HIV who have tried multiple HIV medications in the past (heavily treatment-experienced) and whose HIV infections cannot be successfully treated with other currently available therapies (multidrug resistant HIV, or MDR HIV).Trogarzo is administered intravenously once every 14 days by a trained medical professional and used in combination with other antiretroviral medications. Continue reading.
Today, the U.S. Food and Drug Administration approved Trogarzo (ibalizumab-uiyk), a new type of antiretroviral medication for adult patients living with HIV who have tried multiple HIV medications in the past (heavily treatment-experienced) and whose HIV infections cannot be successfully treated with other currently available therapies (multidrug resistant HIV, or MDR HIV).Trogarzo is administered intravenously once every 14 days by a trained medical professional and used in combination with other antiretroviral medications. Continue reading.
Suscribirse a:
Enviar comentarios (Atom)
No hay comentarios:
Publicar un comentario